Retatrutide Research Peptide (GLP3-R)
Lyophilized Format • ≥99% HPLC Purity • Ships in 1–2 Business Days • U.S. Warehouses
Retatrutide (GLP3-R), also designated LY3437943, is a synthetic triple-receptor agonist peptide supplied by Nextday Peptides for laboratory and analytical research applications. Each vial is independently verified to ≥99% HPLC purity with a Certificate of Analysis available on request. For scientific research use only.
Compound Specifications
| Compound Name | Retatrutide / GLP3-R / LY3437943 |
| Receptor Targets | GLP-1R, GIPR, GCGR (Triple Agonist) |
| Molecular Weight | 4,731.33 g/mol (free base) |
| Molecular Formula | C₁₉₁H₂₉₁N₄₅O₅₈ |
| Form | Lyophilized powder |
| Appearance | White to off-white powder |
| Purity | ≥99% (HPLC verified) |
| Storage | -20°C lyophilized; 2–8°C after reconstitution |
| CAS Number | 2381089-83-2 |
| SKU | NDP-056 |
Mechanism of Action
Retatrutide simultaneously activates three metabolic receptors, distinguishing it from dual agonists such as tirzepatide (GLP-1/GIP only) and single agonists such as semaglutide (GLP-1 only). This triple receptor profile makes it a uniquely valuable reference compound for multi-pathway incretin biology research.
- GLP-1 receptor activation — stimulates glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying in research models
- GIP receptor activation — potentiates insulin secretion and modulates adipose tissue metabolism in preclinical studies
- Glucagon receptor partial agonism — supports hepatic glucose output modulation and increased energy expenditure at physiological concentrations
The simultaneous engagement of all three receptors produces coordinated effects on insulin secretion, glucagon suppression, energy expenditure, and metabolic signaling that are studied in preclinical models and referenced extensively in peer-reviewed literature since Phase 2 trial publications in 2023.
Research Applications
Retatrutide is studied across several active research domains:
- GLP-1/GIP/glucagon receptor crosstalk and downstream signaling pathway studies
- Comparative receptor pharmacology alongside semaglutide and tirzepatide reference compounds
- Metabolic parameter modeling in preclinical rodent and in-vitro models
- Appetite regulation and energy homeostasis investigations
- Insulin secretion, beta cell function, and glucose metabolism research
- Body composition studies examining lean mass and adipose tissue distribution
- Multi-receptor agonist binding affinity and selectivity profiling
Why Research Laboratories Select GLP3-R
Retatrutide is one of the most studied triple-receptor agonist peptides in current metabolic research. Its simultaneous engagement of GLP-1, GIP, and glucagon receptors makes it a valuable reference compound for laboratories investigating multi-pathway receptor biology, energy homeostasis models, and metabolic signaling in preclinical settings.
- Triple receptor profile — GLP-1R, GIPR, and GCGR simultaneous engagement in research models
- Referenced extensively in peer-reviewed literature since Phase 2 trial publications in 2023
- Useful for comparative studies alongside single and dual agonist reference compounds
- Lyophilized format ensures stability and reproducibility across experimental runs
- Batch and lot identifiers on all labeling for full laboratory documentation compliance
Research Background
GLP3-R (Retatrutide) has been referenced in scientific literature as a GLP-1/GIP/glucagon receptor triple agonist. Preclinical studies in rodent and non-human primate models have examined its effects on metabolic parameters. Early-phase human studies have also been conducted and published in peer-reviewed journals. All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance.
Reference sources: PubChem — Retatrutide | Nature — Structural Basis of Triple Agonism
Retatrutide vs. Tirzepatide vs. Semaglutide: Research Comparison
| Compound | Receptor Targets | Agonist Type |
| Retatrutide (GLP3-R) | GLP-1R, GIPR, GCGR | Triple agonist |
| Tirzepatide | GLP-1R, GIPR | Dual agonist |
| Semaglutide | GLP-1R | Single agonist |
This comparison table is provided for research reference only. All compounds listed are supplied for laboratory research use only and are not intended for human use.
Shipping & Fulfillment
- Ships from U.S. warehouses — Florida, North Carolina, and California
- Overnight and 2-day shipping available at checkout
- Same-day processing on orders placed before cutoff
- Discreet packaging with full tracking provided
- Bulk research orders welcome — contact us for volume pricing
Storage & Handling
- Store lyophilized peptide at -20°C away from light and moisture
- After reconstitution, store at 2–8°C and use promptly
- Avoid repeated freeze-thaw cycles to maintain integrity
- Handle using appropriate laboratory safety protocols
- Keep containers sealed when not in use
Frequently Asked Questions — Laboratory Use
What is Retatrutide GLP3-R?
Retatrutide (LY3437943) is a synthetic peptide triple agonist that simultaneously targets GLP-1, GIP, and glucagon receptors. It is supplied strictly for scientific, analytical, and in-vitro laboratory research use only.
How does retatrutide differ from tirzepatide and semaglutide?
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Tirzepatide targets GLP-1 and GIP only (dual agonist). Semaglutide targets GLP-1 only (single agonist). The additional glucagon receptor engagement in retatrutide produces distinct metabolic effects studied in research models.
What purity is your Retatrutide?
Every batch is independently verified to ≥99% HPLC purity. A Certificate of Analysis is available for each lot via our COA Library.
How fast does Nextday Peptides ship?
We ship from U.S. warehouses in Florida, North Carolina, and California. Overnight and 2-day shipping options are available. Most orders process same day.
Are bulk orders available?
Yes. We accommodate bulk research orders. Contact us directly for volume pricing and availability.
Is this product approved for medical use?
No. This product is for laboratory research use only. It is not approved for human or veterinary use, and is not intended for diagnostic, therapeutic, or clinical applications.
What other compounds does Nextday Peptides carry?
We stock a full range of research peptides including Semaglutide GLP-1, Tirzepatide GLP-2T, BPC-157, and TB-500. View our full research compounds catalog.
For Research Use Only — Not for human or veterinary consumption • Not evaluated by the FDA • Supplied by Nextday Peptides for laboratory research applications only